Jon Infante began his research career in 2000 in the field of hereditary ataxias with a series of papers that earned him a PhD in 2003. This line of research has continued uninterrupted to date, from local projects but above all as part of multi-center collaborative international projects in the European Union (EUROSCA, RISCA, ESMI). At the same time, between 2000 and 2006, Dr. Infante participated as a member of the research group of neurodegenerative diseases in the Neurology Service of the University Hospital Marqués de Valdecilla, at that time mainly focused in genetic association studies in Alzheimer’s disease. Since 2006, he has have been working as a PI in the field of genetics and clinical biomarkers in Parkinson's disease. This line of research resulted in 35 original papers published in international journals, two doctoral theses "Parkinson's disease caused by the G2019S mutation of LRRK2 in Cantabria: descriptive study and analysis of biomarkers of the premotor phase of the disease", in 2012, and "Serum levels of uric acid and progranulin, genetic factors that regulate them, and Parkinson's disease", in 2016, as well as several regional, national and international competitive research projects, including three ISCIII/FIS projects (PI070014, PI1100228, PI17/00936). Cantabria is a region with a high prevalence of LRRK2-G2019S carriers (nearly 10% of all PD cases) and this has allowed Dr. Infante’s team to conduct and participate is several projects looking into the prodromal stages of PD. In the academic field, Dr. Infante is a Professor of the Department of Medicine and Psychiatry of the University of Cantabria since 2005, with a permanent position since 2020. As for postgraduate teaching, he has been the Tutor of residents of neurology between 2003 and 2016. In the medical field, Dr. Infante is an specialist in neurology and a Consultant Neurologist in the Cantabrian Health Service since 2001, with a permanent position since 2011. He has carried out his activity uninterruptedly in the Neurology Service of the Marqués de Valdecilla University Hospital in Santander, being appointed Head of Section in December 2015. Since 2016, he is also  the PI of the Neurodegenerative Diseases group of the Marqués de Valdecilla Research Institute (IDIVAL) and also, the PI of the CB06/05/0037 group of CIBERNED (Centro de Investigación en Red de Enfermedades Neurodegenerativas).